article Open AccessTop 1% cited

Intraductal Papillary Mucinous Neoplasms of the Pancreas

Annals of Surgery · 2004 · Vol. 239(6) · pp. 788–799

Taylor A. Sohn✉(Johns Hopkins University)Charles J. Yeo✉(Johns Hopkins University)John L. Cameron✉(Johns Hopkins University)Ralph H. Hruban(Johns Hopkins University)Noriyoshi Fukushima(Johns Hopkins University)Kurtis A. Campbell✉(Johns Hopkins University)Keith D. Lillemoe✉(Johns Hopkins University)

View via DOI Publisher page

Abstract

IPMNs continue to be recognized with increasing frequency. Five-year survival for those patients following resection of IPMNs with invasive cancer (43%) is improved compared with those patients with resected pancreatic ductal adenocarcinoma in the absence of IPMN (averages 15%-25%). Survival following resection of IPMNs without invasive cancer (regardless of degree of dyplasia) is good, but recurrent disease in the residual pancreas suggests that long-term surveillance is critical. Based on the age at resection data, there appears to be a 5-year lag time from IPMN adenoma (63.2 years) to invasive cancer (68.1 years).

Pancreatic and Hepatic Oncology Research Pancreatitis Pathology and Treatment Neuroendocrine Tumor Research AdvancesMedicineIntraductal papillary mucinous neoplasmPancreasPancreatectomyDysplasiaAdenomaPancreaticoduodenectomyAdenocarcinomaPancreatic ductPancreatic cancer

MeSH terms

Biopsy, NeedleAdenocarcinoma, MucinousCarcinoma, PapillaryFemaleHumansImmunohistochemistryMaleNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPancreatectomyPancreatic NeoplasmsPrognosisRetrospective StudiesSurvival Analysis

Citations

871

FWCI

21.11

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Recurrent <i>GNAS</i> Mutations Define an Unexpected Pathway for Pancreatic Cyst Development